Flamel Terminates Biovail License Pact

French biopharmaceutical firm Flamel Technologies SA said it terminated the company's license agreement with Biovail Laboratories Inc. for Genvir, Flamel's oral controlled-release form of acyclovir for the treatment of genital herpes. Flamel's American depositary receipts fell 18 cents to close at $16.18 on the Nasdaq, but plunged $1.59, or 9.8 percent, to $14.59 in after-market activity.

Forbes (http://www.forbes.com/associatedpress/feeds/ap/2005/03/03/ap1862300.html)